Cargando…

INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma

With the introduction of new drugs with different mechanisms of action, multiple myeloma (MM) patients’ outcomes have improved. However, the efficacy seen in clinical trials is often not seen in real-world settings and data on the effectiveness of MM therapies are needed. INSIGHT MM is a prospective...

Descripción completa

Detalles Bibliográficos
Autores principales: Costello, Caitlin, Davies, Faith E, Cook, Gordon, Vela-Ojeda, Jorge, Omel, Jim, Rifkin, Robert M, Berdeja, Jesus, Puig, Noemi, Usmani, Saad Z, Weisel, Katja, Zonder, Jeffrey A, Terpos, Evangelos, Spencer, Andrew, Leleu, Xavier, Boccadoro, Mario, Thompson, Michael A, Romanus, Dorothy, Stull, Dawn M, Hungria, Vania
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6854441/
https://www.ncbi.nlm.nih.gov/pubmed/30816809
http://dx.doi.org/10.2217/fon-2019-0013
_version_ 1783470215155154944
author Costello, Caitlin
Davies, Faith E
Cook, Gordon
Vela-Ojeda, Jorge
Omel, Jim
Rifkin, Robert M
Berdeja, Jesus
Puig, Noemi
Usmani, Saad Z
Weisel, Katja
Zonder, Jeffrey A
Terpos, Evangelos
Spencer, Andrew
Leleu, Xavier
Boccadoro, Mario
Thompson, Michael A
Romanus, Dorothy
Stull, Dawn M
Hungria, Vania
author_facet Costello, Caitlin
Davies, Faith E
Cook, Gordon
Vela-Ojeda, Jorge
Omel, Jim
Rifkin, Robert M
Berdeja, Jesus
Puig, Noemi
Usmani, Saad Z
Weisel, Katja
Zonder, Jeffrey A
Terpos, Evangelos
Spencer, Andrew
Leleu, Xavier
Boccadoro, Mario
Thompson, Michael A
Romanus, Dorothy
Stull, Dawn M
Hungria, Vania
author_sort Costello, Caitlin
collection PubMed
description With the introduction of new drugs with different mechanisms of action, multiple myeloma (MM) patients’ outcomes have improved. However, the efficacy seen in clinical trials is often not seen in real-world settings and data on the effectiveness of MM therapies are needed. INSIGHT MM is a prospective, global, non-interventional, observational study that is enrolling approximately 4200 patients with newly diagnosed or relapsed/refractory MM, making it the largest study of its kind to date. The study aims to describe contemporary, real-world patterns of patient characteristics, clinical disease presentation, therapies chosen, clinical outcomes (response, treatment duration, time-to-next-therapy, progression-free and overall survival), safety, healthcare resource utilization and quality of life. One interim analysis has been conducted to date; current accrual is approximately 3094 patients. Trial registration number: NCT02761187
format Online
Article
Text
id pubmed-6854441
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Future Medicine Ltd
record_format MEDLINE/PubMed
spelling pubmed-68544412019-11-20 INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma Costello, Caitlin Davies, Faith E Cook, Gordon Vela-Ojeda, Jorge Omel, Jim Rifkin, Robert M Berdeja, Jesus Puig, Noemi Usmani, Saad Z Weisel, Katja Zonder, Jeffrey A Terpos, Evangelos Spencer, Andrew Leleu, Xavier Boccadoro, Mario Thompson, Michael A Romanus, Dorothy Stull, Dawn M Hungria, Vania Future Oncol Clinical Trial Protocol With the introduction of new drugs with different mechanisms of action, multiple myeloma (MM) patients’ outcomes have improved. However, the efficacy seen in clinical trials is often not seen in real-world settings and data on the effectiveness of MM therapies are needed. INSIGHT MM is a prospective, global, non-interventional, observational study that is enrolling approximately 4200 patients with newly diagnosed or relapsed/refractory MM, making it the largest study of its kind to date. The study aims to describe contemporary, real-world patterns of patient characteristics, clinical disease presentation, therapies chosen, clinical outcomes (response, treatment duration, time-to-next-therapy, progression-free and overall survival), safety, healthcare resource utilization and quality of life. One interim analysis has been conducted to date; current accrual is approximately 3094 patients. Trial registration number: NCT02761187 Future Medicine Ltd 2019-05 2019-02-28 /pmc/articles/PMC6854441/ /pubmed/30816809 http://dx.doi.org/10.2217/fon-2019-0013 Text en © 2019 Caitlin Costello This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License (http://creativecommons.org/licenses/by-nc-nd/4.0/)
spellingShingle Clinical Trial Protocol
Costello, Caitlin
Davies, Faith E
Cook, Gordon
Vela-Ojeda, Jorge
Omel, Jim
Rifkin, Robert M
Berdeja, Jesus
Puig, Noemi
Usmani, Saad Z
Weisel, Katja
Zonder, Jeffrey A
Terpos, Evangelos
Spencer, Andrew
Leleu, Xavier
Boccadoro, Mario
Thompson, Michael A
Romanus, Dorothy
Stull, Dawn M
Hungria, Vania
INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma
title INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma
title_full INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma
title_fullStr INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma
title_full_unstemmed INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma
title_short INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma
title_sort insight mm: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma
topic Clinical Trial Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6854441/
https://www.ncbi.nlm.nih.gov/pubmed/30816809
http://dx.doi.org/10.2217/fon-2019-0013
work_keys_str_mv AT costellocaitlin insightmmalargeglobalprospectivenoninterventionalrealworldstudyofpatientswithmultiplemyeloma
AT daviesfaithe insightmmalargeglobalprospectivenoninterventionalrealworldstudyofpatientswithmultiplemyeloma
AT cookgordon insightmmalargeglobalprospectivenoninterventionalrealworldstudyofpatientswithmultiplemyeloma
AT velaojedajorge insightmmalargeglobalprospectivenoninterventionalrealworldstudyofpatientswithmultiplemyeloma
AT omeljim insightmmalargeglobalprospectivenoninterventionalrealworldstudyofpatientswithmultiplemyeloma
AT rifkinrobertm insightmmalargeglobalprospectivenoninterventionalrealworldstudyofpatientswithmultiplemyeloma
AT berdejajesus insightmmalargeglobalprospectivenoninterventionalrealworldstudyofpatientswithmultiplemyeloma
AT puignoemi insightmmalargeglobalprospectivenoninterventionalrealworldstudyofpatientswithmultiplemyeloma
AT usmanisaadz insightmmalargeglobalprospectivenoninterventionalrealworldstudyofpatientswithmultiplemyeloma
AT weiselkatja insightmmalargeglobalprospectivenoninterventionalrealworldstudyofpatientswithmultiplemyeloma
AT zonderjeffreya insightmmalargeglobalprospectivenoninterventionalrealworldstudyofpatientswithmultiplemyeloma
AT terposevangelos insightmmalargeglobalprospectivenoninterventionalrealworldstudyofpatientswithmultiplemyeloma
AT spencerandrew insightmmalargeglobalprospectivenoninterventionalrealworldstudyofpatientswithmultiplemyeloma
AT leleuxavier insightmmalargeglobalprospectivenoninterventionalrealworldstudyofpatientswithmultiplemyeloma
AT boccadoromario insightmmalargeglobalprospectivenoninterventionalrealworldstudyofpatientswithmultiplemyeloma
AT thompsonmichaela insightmmalargeglobalprospectivenoninterventionalrealworldstudyofpatientswithmultiplemyeloma
AT romanusdorothy insightmmalargeglobalprospectivenoninterventionalrealworldstudyofpatientswithmultiplemyeloma
AT stulldawnm insightmmalargeglobalprospectivenoninterventionalrealworldstudyofpatientswithmultiplemyeloma
AT hungriavania insightmmalargeglobalprospectivenoninterventionalrealworldstudyofpatientswithmultiplemyeloma